Cargando…

Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

Antibody-drug conjugates (ADCs) represent a novel and promising therapeutic strategy for the treatment of cancer patients. ADCs target antigens highly expressed on the membrane surface of tumor cells to selectively deliver a cytotoxic drug. Ovarian tumors differentially express tumor-specific antige...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manzano, Aranzazu, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464539/ https://www.ncbi.nlm.nih.gov/pubmed/32784819 http://dx.doi.org/10.3390/cancers12082223

Ejemplares similares

Understanding the promising role of antibody drug conjugates in breast and ovarian cancer
por: Babbar, Ritchu, et al.
Publicado: (2023)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020)

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
por: Juan, Alberto, et al.
Publicado: (2020)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
por: Kim, Jung Hoon, et al.
Publicado: (2022)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
por: Li, Wen‐Qian, et al.
Publicado: (2021)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Antibody–drug conjugates as novel anti-cancer chemotherapeutics
por: Peters, Christina, et al.
Publicado: (2015)

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
por: Webster, Emily M., et al.
Publicado: (2020)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
por: Klute, Kelsey, et al.
Publicado: (2014)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
por: Chen, Hao, et al.
Publicado: (2017)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
por: Esnault, Clara, et al.
Publicado: (2022)

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
por: Shi, Fan, et al.
Publicado: (2022)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy
por: Hurwitz, Joshua, et al.
Publicado: (2023)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer
por: Shiomi, Mayu, et al.
Publicado: (2021)

Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
por: Minnix, Megan, et al.
Publicado: (2020)

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
por: Lianos, Georgios D, et al.
Publicado: (2014)

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
por: Mehrling, Thomas, et al.
Publicado: (2018)

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
por: Zhang, Xi-Wen, et al.
Publicado: (2023)

Epigenetic therapy for ovarian cancer: promise and progress
por: Moufarrij, Sara, et al.
Publicado: (2019)

Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
por: Oberoi, Honey K., et al.
Publicado: (2021)

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
por: Domínguez-Llamas, Sandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26pb8s0l4tc4t0bfcb615q60sa